{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T14:50:13Z","timestamp":1774450213597,"version":"3.50.1"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The Y1003S point mutation in exon 14 of mesenchymal-epithelial transition (MET) is a rare mutation that can lead to oncogenic transformation. Few data are available on the characteristics of this mutation. This report presents an elderly patient with non-small cell lung cancer (NSCLC) and a Y1003S mutation in MET detected by next-generation sequencing (NGS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Case Report<\/jats:title><jats:p>In October 2020, a 91-year-old male was admitted to the Department of Respiratory and Critical Care Medicine, Ruijin Hospital because of an increased carcinoembryonic antigen. Imaging revealed highly suspicious lesions in the right upper lobe of the lung, right apex, and left upper lobe with traction of the adjacent pleura. The patient was histologically confirmed as having adenocarcinoma and the MET Y1003S mutation was detected by the NGS subsequently. After evaluation, the patient started crizotinib treatment in December 2020. In the first assessment of tumor response, a chest CT scan in January 2021 showed a partial response. The patient experienced a pulmonary embolism and an abnormal liver function during the treatment and recovered after symptomatic treatment. He maintained a partial response in the last available assessment in July 2021, with the right upper lung lesion being 26 \u00d7 9 mm.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The MET Y1003S mutation was detected in this case, and the patient achieved a partial response using crizotinib. This case highlighted the role of NGS in detecting a rare mutation. Successful remission of complications in such an elderly patient necessitates careful and timely management.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2021.772998","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T06:06:43Z","timestamp":1643609203000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Case Report: A 91-Year-Old Patient With Non-Small Cell Lung Cancer Harboring MET Y1003S Point Mutation"],"prefix":"10.3389","volume":"8","author":[{"given":"Beili","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2217\/crc.12.40","article-title":"Role of HGF\/MET axis in resistance of lung cancer to contemporary management","volume":"1","author":"Raghav","year":"2012","journal-title":"Transl Lung Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1097\/JTO.0b013e31823ab0dd","article-title":"Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort","volume":"6","author":"Yano","year":"2011","journal-title":"J Thorac Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/cas.13156","article-title":"Hepatocyte growth factor\/MET in cancer progression and biomarker discovery","volume":"108","author":"Matsumoto","year":"2017","journal-title":"Cancer Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3389\/fcell.2020.00152","article-title":"Targeting the HGF\/MET axis in cancer therapy: challenges in resistance and opportunities for improvement","volume":"8","author":"Huang","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1093\/annonc\/mdv187","article-title":"2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer","volume":"26","author":"Eberhardt","year":"2015","journal-title":"Ann Oncol"},{"key":"B8","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)\n            EttingerDS\n            WoodDE\n            AisnerDL\n          Fort Washington, MDNational Comprehensive Cancer NetworkNon-Small Cell Lung Cancer. Version 5.20212021"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.21037\/tlcr-20-1113","article-title":"A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations","volume":"10","author":"Santarpia","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1158\/0008-5472.CAN-05-2749","article-title":"Somatic mutations lead to an oncogenic deletion of met in lung cancer","volume":"66","author":"Kong-Beltran","year":"2006","journal-title":"Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1200\/JCO.2016.34.15_suppl.108","article-title":"Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC)","volume":"34","author":"Drilon","year":"2016","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.lungcan.2019.02.002","article-title":"MET Y1003S point mutation shows sensitivity to crizotinib in a patient with lung adenocarcinoma","volume":"130","author":"Miao","year":"2019","journal-title":"Lung Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"820","DOI":"10.3978\/j.issn.2218-6751.2015.12.03","article-title":"MET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of \u201c40 years of wilderness\u201d and into a clear path of regulatory approval","volume":"4","author":"Reungwetwattana","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/JGO.2016.006734","article-title":"Developing CSCO lung cancer practice guidelines stratified by resource availability and treatment value","volume":"3","author":"Zhou","year":"2017","journal-title":"J Glob Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4103\/2278-330X.110506","article-title":"Crizotinib: a comprehensive review","volume":"2","author":"Sahu","year":"2013","journal-title":"South Asian J Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1634\/theoncologist.2014-0241","article-title":"FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements","volume":"19","author":"Kazandjian","year":"2014","journal-title":"Oncologist"},{"key":"B17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.lungcan.2020.08.009","article-title":"Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers","volume":"148","author":"Yang","year":"2020","journal-title":"Lung Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"9632","DOI":"10.1128\/MCB.25.21.9632-9645.2005","article-title":"Met\/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation","volume":"25","author":"Abella","year":"2005","journal-title":"Mol Cell Biol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.jtho.2021.02.010","article-title":"Crizotinib in patients with MET-amplified NSCLC","volume":"16","author":"Camidge","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1097\/JTO.0000000000000491","article-title":"MET-Mutated NSCLC with major response to crizotinib","volume":"10","author":"Mendenhall","year":"2015","journal-title":"J Thorac Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1097\/CAD.0000000000000765","article-title":"Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib","volume":"30","author":"Wang","year":"2019","journal-title":"Anticancer Drugs"},{"key":"B22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41591-019-0716-8","article-title":"Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration","volume":"26","author":"Drilon","year":"2020","journal-title":"Nat Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Investigators: capmatinib in MET Exon 14-mutated or MET-amplified non-small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.772998\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T06:06:48Z","timestamp":1643609208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.772998\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,31]]},"references-count":23,"alternative-id":["10.3389\/fmed.2021.772998"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.772998","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,31]]},"article-number":"772998"}}